
Articles
-
1 day ago |
usnews.com | Sneha K
By Sneha S K(Reuters) - The U.S. Food and Drug Administration said on Tuesday it is starting a process to remove fluoride supplements for children from the market, the latest federal action against the tooth-strengthening mineral. Fluoride is a mineral that occurs naturally in water, soil and air that has been demonstrated to prevent dental cavities and tooth decay. For decades, it has been added to community water supplies and dental products such as toothpaste. U.S. Health Secretary Robert F.
-
1 day ago |
ca.marketscreener.com | Sriparna Roy |Sneha K
(Reuters) - UnitedHealth Group Chief Executive Andrew Witty stepped down suddenly on Tuesday, the company said, as it suspended its 2025 forecast due to surging medical costs, sending its shares plunging more than 11% in morning trading. Former CEO Stephen Hemsley, who has been with the healthcare conglomerate for 28 years, is returning to the top role after stepping down in 2017. Witty chose to leave for personal reasons, the company said, without elaborating.
-
1 day ago |
finance.yahoo.com | Sriparna Roy |Sneha K
By Sriparna Roy and Sneha S K (Reuters) - UnitedHealth Group said its Chief Executive Andrew Witty resigned as of Tuesday, and the company suspended its annual forecast due to surging medical costs, sending shares plunging over 15% to a four-year low. Chairman Stephen Helmsley, 72, who was CEO before stepping down in 2017, will assume the CEO title once again. Witty chose to leave for personal reasons, the company said, without elaborating.
-
2 days ago |
gazette.com | Sriparna Roy |Sneha K
By Sriparna Roy and Sneha S K(Reuters) - UnitedHealth Group Chief Executive Andrew Witty stepped down suddenly on Tuesday, the company said, as it suspended its 2025 forecast due to surging medical costs, sending its shares plunging more than 11% in morning trading. Former CEO Stephen Hemsley, who has been with the healthcare conglomerate for 28 years, is returning to the top role after stepping down in 2017. Witty chose to leave for personal reasons, the company said, without elaborating.
-
2 days ago |
gurutrade.com | Sneha K |Tasim Zahid |Shailesh Kuber
May 12 (Reuters) - Roche Group said on Monday that it plans to invest more than $700 million in a new drug manufacturing facility in North Carolina, the latest drugmaker to expand its presence in the United States amid President Donald Trump's tariff policies. The new facility, based in Holly Springs, North Carolina, will support Roche and its unit Genentech's future portfolio of next-generation obesity medicines.
Try JournoFinder For Free
Search and contact over 1M+ journalist profiles, browse 100M+ articles, and unlock powerful PR tools.
Start Your 7-Day Free Trial →